School of Medicine
Showing 11-20 of 23 Results
-
Andrey Finegersh, MD, PhD
Assistant Professor of Otolaryngology - Head & Neck Surgery (OHNS)
BioDr. Finegersh is a fellowship-trained head and neck surgical oncologist with board certification in otolaryngology and an Assistant Professor with the Stanford School of Medicine Department of Otolaryngology.
He specializes in treatment of benign and malignant tumors of the head and neck and has received additional training in microvascular reconstruction and transoral robotic surgery. He takes tremendous pride in providing compassionate care for patients and managing challenging diagnoses.
Dr. Finegersh completed his MD and PhD degrees at the University of Pittsburgh School of Medicine's combined Medical Scientist Training Program. He went on to complete residency in otolaryngology at the University of California San Diego (UCSD) and his fellowship at Stanford University, where he stayed on as faculty.
He has extensive research experience in head and neck cancer epigenetics and completed post-doctoral research at the University of Pittsburgh and UCSD. He has received grants from the NIH and American Academy of Otolaryngology and has an active research lab studying molecular mechanisms of cancer. Dr. Finegersh has additional clinical interests in studying the role of minimally invasive surgery to improve outcomes for head and neck cancer patients. -
Andrew Fire
George D. Smith Professor of Molecular and Genetic Medicine and Professor of Pathology and of Genetics
Current Research and Scholarly InterestsWhile chromosomal inheritance provides cells with one means for keeping and transmitting genetic information, numerous other mechanisms have (and remain to be) discovered. We study novel cellular mechanisms that enforce genetic constancy and permit genetic change. Underlying our studies are questions of the diversity of inheritance mechanisms, how cells distinguish such mechanisms as "wanted" versus "unwanted", and of the consequences and applications of such mechanisms in health and disease.
-
Michael Fischbach
Liu (Liao) Family Professor
Current Research and Scholarly InterestsThe microbiome carries out extraordinary feats of biology: it produces hundreds of molecules, many of which impact host physiology; modulates immune function potently and specifically; self-organizes biogeographically; and exhibits profound stability in the face of perturbations. Our lab studies the mechanisms of microbiome-host interactions. Our approach is based on two technologies we recently developed: a complex (119-member) defined gut community that serves as an analytically manageable but biologically relevant system for experimentation, and new genetic systems for common species from the microbiome. Using these systems, we investigate mechanisms at the community level and the strain level.
1) Community-level mechanisms. A typical gut microbiome consists of 200-250 bacterial species that span >6 orders of magnitude in relative abundance. As a system, these bacteria carry out extraordinary feats of metabolite consumption and production, elicit a variety of specific immune cell populations, self-organize geographically and metabolically, and exhibit profound resilience against a wide range of perturbations. Yet remarkably little is known about how the community functions as a system. We are exploring this by asking two broad questions: How do groups of organisms work together to influence immune function? What are the mechanisms that govern metabolism and ecology at the 100+ strain scale? Our goal is to learn rules that will enable us to design communities that solve specific therapeutic problems.
2) Strain-level mechanisms. Even though gut and skin colonists live in communities, individual strains can have an extraordinary impact on host biology. We focus on two broad (and partially overlapping) categories:
Immune modulation: Can we redirect colonist-specific T cells against an antigen of interest by expressing it on the surface of a bacterium? How do skin colonists induce high levels of Staphylococcus-specific antibodies in mice and humans?
Abundant microbiome-derived molecules: By constructing single-strain/single-gene knockouts in a complex defined community, we will ask: What are the effects of bacterially produced molecules on host metabolism and immunology? Can the molecular output of low-abundance organisms impact host physiology?
3) Cell and gene therapy. We have begun two new efforts in mammalian cell and gene therapies. First, we are developing methods that enable cell-type specific delivery of genome editing payloads in vivo. We are especially interested in delivery vehicles that are customizable and easy to manufacture. Second, we have begun a comprehensive genome mining effort with an emphasis on understudied or entirely novel enzyme systems with utility in mammalian genome editing. -
George A. Fisher Jr.
Colleen Haas Chair in the School of Medicine, Emeritus
Current Research and Scholarly InterestsClinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.
-
Paul Graham Fisher, MD
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health
Current Research and Scholarly InterestsClinical neuro-oncology: My research explores the epidemiology, natural history, and disease patterns of brain tumors and other cancers in childhood, as well as prospective clinical trials for treating these neoplasms. Research interests also include neurologic effects of cancer and its therapies.
-
James Ford
Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics
Current Research and Scholarly InterestsMammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.
-
Ines Forrest
Postdoctoral Scholar, Stanford Cancer Institute
BioI completed a dual Master's Degree in Chemistry/Biochemistry (University of Oklahoma) and Organic Chemistry/Chemical Engineering (Sigma-Clermont), as well as a Ph.D. in Chemical and Biological Sciences (The Scripps Research Institute). As a postdoctoral research fellow at Stanford in Prof. Nathanael Gray's lab, I look forward to applying my skills in chemical proteomics, chemistry, and molecular biology to drive impactful research at the interface of chemistry and medicine and develop pioneering solutions to improve human health.
-
Matthew Frank
Assistant Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Matthew Frank, MD, PhD, is an Assistant Professor of Medicine in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Frank predominantly cares for patients with high-risk lymphoma and other blood cancers. He is a lead investigator of clinical trials evaluating the safety and effectiveness of cancer treatments called chimeric antigen receptor (CAR ) T therapy for patients with lymphomas and leukemias. Dr. Frank’s research focuses on developing methods to identify patients who are at high risk for relapse or developing side-effects after receiving CAR T therapy and to understand why these relapses and side-effects occur.
-
Hunter Fraser
Professor of Biology
Current Research and Scholarly InterestsWe study the evolution of complex traits by developing new experimental and computational methods.
Our work brings together quantitative genetics, genomics, epigenetics, and evolutionary biology to achieve a deeper understanding of how genetic variation shapes the phenotypic diversity of life. Our main focus is on the evolution of gene expression, which is the primary fuel for natural selection. Our long-term goal is to be able to introduce complex traits into new species via genome editing.
